Jeffrey Kindler Net Worth

The estimated Net Worth of Jeffrey B Kindler is at least $1.38 Million dollars as of 14 May 2024. Mr. Kindler owns over 8,764 units of Perrigo plc stock worth over $727,430 and over the last 12 years he sold PRGO stock worth over $251,327. In addition, he makes $399,976 as Independent Director at Perrigo plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Kindler PRGO stock SEC Form 4 insiders trading

Jeffrey has made over 32 trades of the Perrigo plc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 8,764 units of PRGO stock worth $264,848 on 14 May 2024.

The largest trade he's ever made was exercising 106,837 units of Perrigo plc stock on 9 March 2024 worth over $2,855,753. On average, Jeffrey trades about 8,585 units every 47 days since 2012. As of 14 May 2024 he still owns at least 27,214 units of Perrigo plc stock.

You can see the complete history of Mr. Kindler stock trades at the bottom of the page.

Jeffrey Kindler biography

Jeffrey B. Kindler serves as Independent Director of the Company. Mr. Kindler has served as CEO of Centrexion Corporation, a privately held bio therapeutics company that develops pain therapies, since 2013. He also serves as a Managing Director at Starboard Capital Partners and an advisor to a number of healthcare companies. Prior to this, Mr. Kindler was a Venture Partner at Lux Capital from 2012 until January 2020, Executive Chairman of vTv from July 2015 to November 2019, Chairman and CEO of Pfizer, Vice President of Litigation and Legal Policy at General Electric Company, Executive Vice President and General Counsel at McDonald’s, and President at Partner Brands. In addition, Mr. Kindler has been a director of Intrexon, now known as Precigen since 2011, vTv Therapeutics since 2015 and PPD since February 2020 when PDD became a public company. Based on an 8-K filed on March 6, 2020, Mr. Kindler will not stand for re-election as a director of Siga Technologies, where he has served as a director since 2013, such that his service on that board will end at Siga’s next AGM, which is expected to be in May 2020.

What is the salary of Jeffrey Kindler?

As the Independent Director of Perrigo plc, the total compensation of Jeffrey Kindler at Perrigo plc is $399,976. There are 13 executives at Perrigo plc getting paid more, with Murray Kessler having the highest compensation of $10,807,800.

How old is Jeffrey Kindler?

Jeffrey Kindler is 64, he's been the Independent Director of Perrigo plc since 2017. There are 5 older and 22 younger executives at Perrigo plc. The oldest executive at Perrigo Company plc is Rolf Classon, 75, who is the Independent Director.

What's Jeffrey Kindler's mailing address?

Jeffrey's mailing address filed with the SEC is C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN, MI, 49010.

Insiders trading at Perrigo plc

Over the last 11 years, insiders at Perrigo plc have traded over $21,020,805 worth of Perrigo plc stock and bought 592,512 units worth $38,708,035 . The most active insiders traders include Jeffrey C Smith, Gary M Cohen, and Joseph C Papa. On average, Perrigo plc executives and independent directors trade stock every 11 days with the average trade being worth of $156,424. The most recent stock trade was executed by Ronald Craig Janish on 26 August 2024, trading 13,000 units of PRGO stock currently worth $382,200.

What does Perrigo plc do?

perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).

Complete history of Mr. Kindler stock trades at vTv Therapeutics Inc, Chipotle Mexican Grill, Perrigo plc, SIGA Technologies Inc, PPD Inc, and Precigen Inc

Perrigo plc executives and stock owners

Perrigo plc executives and other stock owners filed with the SEC include:

• Murray Kessler,
  President, Chief Executive Officer, Director
• Raymond Silcock,
  Chief Financial Officer, Executive Vice President
• Murray S. Kessler,
  CEO, Pres & Director
• Todd Kingma,
  Executive Vice President, General Counsel, Company Secretary
• James Dillard,
  Executive Vice President, Chief Scientific Officer
• Svend Andersen,
  Executive Vice President, President - Consumer Healthcare International
• Sharon Kochan,
  Executive Vice President, President - RX Pharmaceuticals
• Raymond P. Silcock,
  CFO, Principal Accounting Officer & Exec. VP
• Svend Andersen,
  Exec. VP & Pres of Consumer Healthcare International
• Richard S. Sorota,
  Exec. VP & Pres of Consumer Self-Care Americas
• Todd W. Kingma,
  Exec. VP, Gen. Counsel & Sec.
• James E. Dillard III,
  Exec. VP & Pres of Consumer Self-Care Americas
• Rolf Classon,
  Independent Director
• Donal O'Connor,
  Independent Director
• Jeffrey Kindler,
  Independent Director
• Theodore Samuels,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Bradley Alford,
  Independent Director
• Adriana Karaboutis,
  Independent Director
• Erica Mann,
  Independent Director
• Bradley Joseph,
  Vice President Global Investor Relations
• Katherine Doyle,
  Director
• Rich Sorota,
  Executive Vice President and President - Consumer Self-Care Americas
• Grainne Quinn,
  Executive Vice President, Chief Medical Officer
• Ronald Janish,
  Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer
• Thomas Farrington,
  Executive Vice President, Chief Information Officer
• Robert Willis,
  Chief Human Resource Officer, Executive Vice President
• Kyle L. Hanson,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Alison Ives,
  Exec. VP & Chief Scientific Officer
• Eduardo Guarita Bezerra,
  Exec. VP & CFO
• Mary Reilly-Brest,
  Director of Global Organizational and Human Resource Devel.
• Thomas M. Farrington,
  Chief Information Officer & Exec. VP
• Shannon Hukill,
  Sr. Director of Technical Operations
• Ronald C. Janish,
  Chief Transformation Officer and Exec. VP of Global Operations & Supply Chain
• Patrick Lockwood Taylor,
  CEO
• Paul Weninger,
  EVP, Quality Operations
• James R Michaud,
  EVP, Chief HR Officer
• John T Hendrickson,
  EVP Global Operations & Supply
• Gary M Cohen,
  Director
• John Wesolowski,
  EVP, President Rx
• Michael J Jandernoa,
  Director
• Judy L Brown,
  Executive VP & CFO
• Laurie Brlas,
  Director
• Jeffrey C Smith,
  Director
• Triona Schmelter,
  EVP & President CSCA
• Uwe Roehrhoff,
  CEO
• Ronald Winowiecki,
  CFO
• David Ball,
  EVP & CBDO
• Jacqualyn A Fouse,
  Director
• Ellen Randi Hoffing,
  Director
• Louis Yu,
  Executive VP Global Quality
• Shlomo Yanai,
  Director
• Marc Coucke,
  Executive VP & GM
• Michael Robert Stewart,
  Sr. VP Global Human Resources
• Joseph C Papa,
  President and CEO
• Gary K Jr Kunkle,
  Director
• Herman Jr Morris,
  Director
• Ben Zion Zilberfarb,
  Director
• Ran Gottfried,
  Director
• Jatin Shah,
  Sr VP & Chief Scientific Offic
• Scott F Jamison,
  
• David T Gibbons,
  Director
• Douglas Boothe,
  EVP & GM Perrigo Pharma
• Jeffrey Needham,
  EVP, President CHC Americas
• Orlando D Ashford,
  Director
• Alison Ives,
  EVP & Chief Scientific Officer
• Kyle Hanson,
  EVP & General Counsel
• Eduardo Guarita Bezerra,
  EVP & Chief Financial Officer
• Albert Manzone,
  Director
• Julia M Brown,
  Director